Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0086543 (cataract)
 29,165 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We reexamined the eyes of 39 nephrotic children to investigate further the relationship between oral corticosteroid therapy and posterior subcapsular cataract formation. The corticosteroid dosage was proportional to each patient's weight. Six children had posterior subcapsular cataracts an average of 16 months after the first examination. Nine patients had complete regression of their posterior subcapsular cataracts. We found no correlation between the age at onset of the nephrotic syndrome, the dosage or duration of corticosteroid therapy, or the renal biopsy findings and posterior subcapsular cataract formation. Cushingoid manifestations were significantly more common in the patients with posterior subcapsular cataracts. These patients may be more sensitive to the effects of corticosteroids than those who never had cataracts and those whose cataracts regressed.
 ...
PMID:Reversibility of corticosteroid-associated cataracts in children with the nephrotic syndrome. 90 Feb 21

Glucocorticoids are the mainstay of treatment for GCA. Patients often require long-term treatment that may be associated with numerous adverse effects, depending on the dose and the duration of treatment. Trends in recent decades for glucocorticoid use in GCA suggest increasing cumulative doses and longer exposures. Common adverse events (AEs) reported in glucocorticoid-treated GCA patients include osteoporosis, hypercholesterolaemia, hypertension, posterior subcapsular cataract, infections, diabetes mellitus, Cushingoid appearance, adrenal insufficiency and aseptic necrosis of bone. AEs considered most worrisome by patients and rheumatologists include weight gain, psychological effects, osteoporosis, cardiometabolic complications and infections. The challenge is to maximize the benefit-risk ratio by giving the maximum glucocorticoid treatment necessary to control GCA initially and then to prevent relapse but to give the minimum treatment possible to avoid glucocorticoid-related AEs. We discuss the safety issues associated with long-term glucocorticoid use in patients with GCA and strategies for preventing glucocorticoid-related morbidity.
 ...
PMID:Prevention of glucocorticoid morbidity in giant cell arteritis. 2998 79